Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Operating Income (2016 - 2025)

Historic Operating Income for Ascendis Pharma A (ASND) over the last 12 years, with Q4 2025 value amounting to $11.5 million.

  • Ascendis Pharma A's Operating Income rose 271485.71% to $11.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$145.2 million, marking a year-over-year increase of 5204.25%. This contributed to the annual value of -$154.0 million for FY2025, which is 4830.21% up from last year.
  • Ascendis Pharma A's Operating Income amounted to $11.5 million in Q4 2025, which was up 271485.71% from $12.9 million recorded in Q3 2025.
  • In the past 5 years, Ascendis Pharma A's Operating Income registered a high of $12.9 million during Q3 2025, and its lowest value of -$154.2 million during Q1 2023.
  • Over the past 5 years, Ascendis Pharma A's median Operating Income value was -$135.2 million (recorded in 2021), while the average stood at -$103.4 million.
  • Examining YoY changes over the last 5 years, Ascendis Pharma A's Operating Income showed a top increase of 271485.71% in 2025 and a maximum decrease of 10532.03% in 2025.
  • Ascendis Pharma A's Operating Income (Quarter) stood at -$128.8 million in 2021, then decreased by 16.76% to -$150.4 million in 2022, then skyrocketed by 73.8% to -$39.4 million in 2023, then soared by 101.04% to $409272.0 in 2024, then soared by 2714.86% to $11.5 million in 2025.
  • Its last three reported values are $11.5 million in Q4 2025, $12.9 million for Q3 2025, and -$59.9 million during Q2 2025.